| Description |
1 online resource (288 pages) |
| Contents |
Cover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Preface -- List of Abbreviations -- Chapter 1 Genomic Strategies for Personalized Cancer Therapy -- 1.1 Introduction -- 1.1.1 Definition of Precision Medicine in Oncology -- 1.1.2 DNA and RNA Sequencing Techniques -- 1.2 Precision Medicine in Specific Tumors -- 1.2.1 Lung Cancer -- 1.2.1.1 Adenocarcinoma -- 1.2.1.2 Squamous Cell Carcinoma -- 1.2.1.3 Small-Cell Lung Carcinoma (SCLC) -- 1.2.1.4 Epidermal Growth Factor Receptor (EGFR) Mutations -- 1.2.1.5 Anaplastic Lymphoma Kinase (ALK) -- 1.2.1.6 BRAF, ROS1, MET |
|
1.2.1.7 KRAS -- 1.2.1.8 Other: RET, NTRK -- 1.2.2 Head and Neck Cancers -- 1.2.2.1 HPV-Positive Cancers -- 1.2.2.2 HPV-Negative Cancers -- 1.2.2.3 Targeting the Epidermal Growth Factor Receptor (EGFR) Pathway -- 1.2.2.4 Thyroid Cancers -- 1.2.2.5 Other Targets -- 1.2.3 Hematological Malignancies -- 1.2.3.1 Lymphoma -- 1.2.3.2 Leukemia -- 1.2.3.3 Myelodysplastic Syndrome -- 1.2.4 Gynecologic Malignancies -- 1.2.4.1 Cervical -- 1.2.4.2 Uterine -- 1.2.4.3 Ovarian -- 1.2.5 Melanoma -- 1.2.6 Gastrointestinal Malignancies -- 1.2.6.1 Gastroesophageal Cancers -- 1.2.6.2 Colorectal Cancers |
|
1.2.7 Breast Cancer -- 1.2.7.1 Basal-Like, or Triple Negative Breast Cancer -- 1.2.7.2 Luminal A/B, or Hormone Positive -- 1.2.7.3 HER2 Positive Breast Cancer -- 1.2.7.4 Immunotherapy -- 1.2.7.5 Germline Testing in Breast Cancer -- 1.2.7.6 Conclusion -- 1.2.8 Genitourinary Malignancies -- 1.2.8.1 Prostate Cancer -- 1.2.8.2 Renal Cell Cancer (RCC) -- 1.2.8.3 Urothelial Cancers -- 1.2.9 Pediatric Cancers -- 1.2.9.1 Introduction -- 1.2.9.2 Leukemia and Lymphoma -- 1.2.9.3 Central and Peripheral Nervous System Tumors -- 1.2.9.4 Bone and Soft Tissue Sarcomas -- 1.2.9.5 Other Embryonal Tumors |
|
1.2.9.6 Conclusion -- 1.2.10 Cancers of Unknown Primary Origin -- 1.2.10.1 Diagnosis -- 1.2.10.2 Gene Expression Profiling -- 1.2.10.3 Mutational Testing with Next-Generation Sequencing (NGS) -- 1.2.10.4 Treatment -- 1.3 Biomarkers for Immunotherapy of Cancer -- 1.3.1 PD-L1 -- 1.3.2 Soluble PD-L1 (sPD-L1) -- 1.3.3 Combined Positive Score (CPS) -- 1.3.4 Tumor Microenvironment -- 1.3.5 Tumor Mutational Burden (TMB) -- 1.3.6 Microsatellite Instability (MSI) -- 1.3.7 MMR Deficiency -- 1.3.8 Peripheral Blood Absolute Neutrophil Count/Absolute Lymphocyte Count -- 1.3.9 Microbiome |
|
1.4 Clinical Trial Design in the Era of Precision Oncology -- 1.5 Ethical, Legal, and Social Issues of Precision Oncology -- 1.5.1 Ethical Issues -- 1.5.2 Legal Issues -- 1.5.3 Social Issues -- 1.6 Databases, Data Sharing, and Challenges of Precision Oncology -- References -- Chapter 2 Blood-Based Biomarkers for the Diagnosis and Prognosis of Cancer -- 2.3 Circulating Proteins as Biomarkers -- 2.4 Circulating Long Non-coding RNAs as Biomarkers -- 2.5 Circulating miRNAs as Biomarkers -- 2.6 Circulating Autoantibodies as Biomarkers -- 2.7 Circulating Tumor DNA as Biomarkers |
| Notes |
List of Contributors Preface List of Abbreviations Chapter 1 Genomic Strategies for Personalized Cancer Therapy Chapter 2 Blood-based biomarkers for the diagnosis and prognosis of cancer Chapter 3 Application of circulating cell free DNA for personalized cancer therapy Chapter 4 Prognostic Implications of EGFR, p53, p16, cyclin D1, Bcl-2 in Head & Neck Squamous Cell Carcinoma (HNSCC) Chapter 6 Predictive and prognostic markers for cancer medicine Chapter 7 Dual Energy Imaging in Precision Radiation Therapy Chapter 8 The role of Big Data in personalized medicine |
|
Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force. WlAbNL |
| Subject |
Cancer -- Radiotherapy.
|
|
Radiation Oncology
|
|
Cancer -- Radiotherapy
|
| Form |
Electronic book
|
| Author |
Aydogan, Bulent, editor
|
|
Radosevich, James A., editor
|
| LC no. |
2020012104 |
| ISBN |
9781119432494 |
|
1119432499 |
|
9781119432456 |
|
1119432456 |
|
